Filter

Refine by Content Type

Refine by ASN Kidney News

  • Features (1)

Refine by Date

—
  • Print
  • Save

Search Results

You are looking at 1 - 1 of 1 items for :

  • Author or Editor: Swapnil Hiremath x
  • Refine by Content Type: All x
Clear All Modify Search
Cover Kidney News
This Is the Way: Randomized Clinical Trial Shows ACEis and ARBs Can Safely Be Continued in Patients with COVID-19
Swapnil Hiremath and Matthew A. Sparks

Severe acute respiratory coronavirus 2 (SARS-CoV-2) uses angiotensin-converting enzyme 2 (ACE2) to enter host cells. Early in the pandemic, several basic science studies were often cited and suggested that ACE inhibitors (ACEis) and angiotensin receptor blockers (ARBs) may have an effect to increase the abundance of ACE2 (1). Thus, logic would prevail that if anyone on ACEis or ARBs is at risk of infection, becomes infected, or develops coronavirus infectious disease 2019 (COVID-19), then these should be discontinued. However, the science of the renin angiotensin system (RAS) is far more intricate and interesting. The correct answer is that